| Document Date: 2012-04-18 11:56:06
Open Document File Size: 100,37 KBShare Result on Facebook
City CAMBRIIDGE / Cambridge / Osaka / / Company Takeda Pharmaceutical Company Limited / Janssen Pharmaceutical K.K. / VEL LCADE.com. / Takeeda Pharmaceeutical Company / Milllennium Pharm / Takeda Oncology Company / Takeda Pharm / / Continent Europe / / Country Japan / United States / / Event FDA Phase / / Facility Massachusetts General Hospital Cancer Center / / IndustryTerm pharmaceuticals / treatment of patients with mantle cell lymphoma / / MedicalCondition percent Neuralgia / multiple myeloma / fainting / developin ng peripheral neuropathy / seen insomnia / mantle cell lymphoma / Symptoms incclude cough / percent Thrombocytopenia / Nausea / diabetes / muscle weakness / fever / Tumor lysis syndrome / Peripheral neuropathy / pain / heart failure / dizziness / nd mantle celll lymphoma aafter / light headedness / / Organization FDA / Massachusetts General Hospital Cancer Center / / Person Karen Ferrante / Noopur Raje / / / Position Chief Meddical Officer / / Product VELCADE / mannitol / VELCAD DE®(bortezom mib) / Safety Information VELCADE® (bortezomib) / / ProvinceOrState Massachusetts / / URL www.milllennium.com//InTheNews.aaspx / www.takeeda.com / www.milllennium.com / /
SocialTag |
Microsoft Word - SC VELCADE Press Release - FINAL[removed]